Type 1 interferons as a potential treatment against COVID-19 - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Antiviral Research Year : 2020

Type 1 interferons as a potential treatment against COVID-19

Abstract

Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.

Domains

Virology Emerging diseases
Fichier principal
Vignette du fichier
S0166354220302059.pdf (180.88 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Accord Elsevier CCSD  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-02546137

Submitted on : Monday, August 22, 2022-10:33:00 AM

Last modification on : Thursday, February 2, 2023-5:00:08 PM

Long-term archiving on: Wednesday, November 23, 2022-7:31:05 PM

Download

Dates and versions

inserm-02546137 , version 1 (22-08-2022)

Licence

Attribution - NonCommercial

Identifiers

Elsevier-hosted Accepted Manuscript

Cite

Erwan Sallard, François-Xavier Lescure, Yazdan Yazdanpanah, France Mentré, Nathan Peiffer-Smadja. Type 1 interferons as a potential treatment against COVID-19. Antiviral Research, 2020, 178, pp.104791. ⟨10.1016/j.antiviral.2020.104791⟩. ⟨inserm-02546137⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM UNIV-PARIS13 ENS-PARIS PSL USPC SORBONNE-PARIS-NORD UP-SANTE
242 View
28 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More